Viridium Shares to Commence Trading On October 10, 2017 and Viridium Proceeding with a Private Placement
Calgary, Alberta (FSCwire) - Further to its News Release dated October 2, 2017, Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR, OTCPink: MRRBF) confirms that it has received TSX Venture Exchange Final Acceptance (the “Final Acceptance”) of its reverse take-over transaction through which over 81% of the shares and debentures of Experion Biotechnologies Inc. (“Experion”) were acquired (the “Transaction”). As a result of the receipt of the Final Acceptance the Viridium common shares are expected to commence trading on the TSX Venture Exchange on October 10, 2017. The Viridium shares will trade on the TSX Venture Exchange under the symbol VIR.
As a result of the receipt of the Final Acceptance, all conditions for the Transaction and the previous private placement offering raising $3.3 million have been satisfied and are now closed. It is anticipated that the completion of the acquisition of the remaining approximate 19% of Experion shares will be completed by on or before October 13, 2017.
Viridium also confirms that it has filed its Material Change Report on SEDAR.com.
Private Placement Offering
Viridium is proceeding to raise additional funds of up to $600,000 by way of a non-brokered private placement (the “Offering”). Terms of the Offering will, in all material respects, be identical to the terms of the offering recently concluded and described in the News Release dated October 2, 2017. However, unlike the previous private placement, there is no commission payable in regard to this Offering.
Pursuant to the Offering, the Company intends to issue up to a minimum of 1,000,000 Units at a price of $0.60 per Unit.
Each Unit will consist of one common share and one-half of one common share purchase warrant (the “Unit”) (each whole common share purchase warrant hereinafter referred to as the “Warrant”), with each Warrant being exercisable to acquire one common share of the Company at a price of $0.80 expiring on June 27, 2018.
The Offering will be conducted pursuant to available prospectus exemptions under applicable securities laws, including sales to accredited investors and family, friends and business associates. Completion of the Offering is subject to receipt of Exchange approval and other requisite approvals. All of the securities issuable in connection with the Offering will be subject to a hold period expiring four months and one day after the date of issuance.
Upon closing of the Offering will be used to proceed with the business of Viridium.
Steve Serenas, CEO of Viridium, stated, “I want to thank everyone involved in completing the transaction and the offerings related thereto. We have achieved a great level of success having received our ACMPR license to produce cannabis and, very shortly, becoming listed on the TSX Venture Exchange. This has made it a wonderful Thanksgiving weekend and we wish to thank our shareholders, directors and staff for their support and look forward to moving Viridium forward”.
Not a United States Offer: This press release does not constitute an offer of securities for sale in the United States or to “U.S. persons” (“U.S. persons”), as such term is defined in Regulation S promulgated under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities being offered have not been, nor will be, registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from such registration requirements.
Disclosure
The TSX Venture Exchange has in no way passed upon the merits of the proposed Reverse Take-over Transaction and has neither approved nor disapproved the contents of this news release.
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company's equity securities; recent market volatility; the Company's ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management's Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.
For further information:
VIRIDIUM PACIFIC GROUP LTD.
John Zang
Corporate Secretary
Telephone: 403 680 9264
Email: jzanglaw@gmail.com
To view this press release as a PDF file, click onto the following link:public://news_release_pdf/viridium10102017.pdf
Source: Viridium Pacific Group Ltd. (TSX Venture:VIR)
To follow Viridium Pacific Group Ltd. on your favorite social media platform or financial websites, please click on the icons below.
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2017 Filing Services Canada Inc.